拉米夫定联合阿德福韦酯或臭氧与拉米夫定对比治疗乙肝一年
 |
| 第1页 |
参见附件。
【摘要】 目的：分析研究拉米夫定联合阿德福韦酯或医用臭氧与拉米夫定对比治疗乙肝一年的疗效。方法：对我院2010年1月-2010年12月收治的180例慢性乙肝患者采用拉米夫定联合阿德福韦酯或医用臭氧进行一年的治疗，并将疗效与单用LAM的疗效进行比较。结果：治疗48周后，组1的联合应答率为33.33%，部分应答68.33%；组2的联合应答率为20.00%，部分应答66.67%；组3的联合应答率5.26%，部分应答率为36.66%，组3的疗效与组1、组2两组存在明显差异(P<0.05)。结论：LAM联合阿德福韦酯或臭氧治疗乙肝值得在临床上推广应用。
【关键词】 拉米夫定; 阿德福韦酯; 医用臭氧; 乙肝
【中国分类号】 R512【文献标识码】 A【文章编号】 1044-5511(2012)02-0328-02
【Abstract】 Objective: the efficacy of lamivudine combined with analysis of adefovir dipivoxil or medical ozone and lamivudine compared the treatment of hepatitis B for one year. Methods: 180 cases of chronic hepatitis B patients admitted to hospital in January 2010 -2010 December lamivudine combined with adefovir dipivoxil or medical ozone for one year of treatment, and efficacy with a single efficacy of LAM for comparison. Results: After 48 weeks of treatment, group 1 joint response rate of 33.33%, partial response 68.33%; group 2 combined response rate of 20.00%, 66.67% partial response; group 3 combined response rate of 5.26%, partial response rate of 36.66%, the efficacy of group 3 and group 1, group 2 the two groups significantly different (P <0 ......
您现在查看是摘要介绍页，详见PDF附件。